Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosunetuzumab + zanubrutinib
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Mosunetuzumab + zanubrutinib is a combination therapy consisting of mosunetuzumab, a bispecific antibody that targets CD20 on B cells and CD3 on T cells, and zanubrutinib, a next-generation Bruton's tyrosine kinase (BTK) inhibitor. This combination is being investigated for the treatment of various B-cell malignancies, particularly follicular lymphoma. The dual mechanism of action combines T-cell engagement against CD20-expressing B cells with inhibition of B-cell receptor signaling through BTK blockade, potentially offering synergistic anti-lymphoma activity.
02
Targets
Beyond the preview
Go deeper on mosunetuzumab + zanubrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosunetuzumab + zanubrutinib.